China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection

China Pharma Holdings, Inc. ("China Pharma") which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, announced today that it has received approval from the Chinese State Food and Drug Administration (SFDA) for the production of generic Bumetanide injection which is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome by inducing dieresis.